105 related articles for article (PubMed ID: 3266444)
1. [The efficacy of recombinant interleukin 2 in local treatment of superficial bladder tumors].
Fujioka T; Shiraishi M; Tanji S; Sato S; Koike H; Aoki H; Suzuki K; Kumagai K; Banya Y; Kubo T
Hinyokika Kiyo; 1988 Dec; 34(12):2115-9. PubMed ID: 3266444
[TBL] [Abstract][Full Text] [Related]
2. Local/regional recombinant interleukin 2 (rIL-2) immunotherapy of tumors. Intra-arterial continuous infusion of rIL-2 in bladder cancer patients: a phase I study.
Velotti F; Tubaro A; Stoppacciaro A; Pettinato A; Morrone S; Bossola P; Napolitano T; Miano L; Ruco L; Piccoli M
Ann Ist Super Sanita; 1990; 26(3-4):411-21. PubMed ID: 2091503
[TBL] [Abstract][Full Text] [Related]
3. Recombinant interleukin-2 and lymphokine-activated killer cell treatment of advanced bladder cancer: clinical results and immunological effects.
Hermann GG; Geertsen PF; von der Maase H; Steven K; Andersen C; Hald T; Zeuthen J
Cancer Res; 1992 Feb; 52(3):726-33. PubMed ID: 1732060
[TBL] [Abstract][Full Text] [Related]
4. Local activation of immune response in bladder cancer patients treated with intraarterial infusion of recombinant interleukin-2.
Velotti F; Stoppacciaro A; Ruco L; Tubaro A; Pettinato A; Morrone S; Napolitano T; Bossola PC; Franks CR; Palmer P
Cancer Res; 1991 May; 51(9):2456-62. PubMed ID: 2015606
[TBL] [Abstract][Full Text] [Related]
5. Local continuous high dose interleukin 2: a new therapeutic model for the treatment of advanced bladder carcinoma.
Huland E; Huland H
Cancer Res; 1989 Oct; 49(19):5469-74. PubMed ID: 2788500
[TBL] [Abstract][Full Text] [Related]
6. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study.
Yutkin V; Pode D; Pikarsky E; Mandelboim O
J Urol; 2007 Dec; 178(6):2660-4. PubMed ID: 17945285
[TBL] [Abstract][Full Text] [Related]
7. Neoadiuvant treatment with intravesical interleukin-2 for recurrent superficial transitional bladder carcinoma Ta-T1/G1-2.
Grasso M; Torelli F; Scannapieco G; Franzoso F; Lania C
J Immunother; 2001; 24(2):184-7. PubMed ID: 11265776
[TBL] [Abstract][Full Text] [Related]
8. Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation.
Lauria F; Raspadori D; Ventura MA; Rondelli D; Zinzani PL; Gherlinzoni F; Miggiano MC; Fiacchini M; Rosti G; Rizzi S; Tura S
Bone Marrow Transplant; 1996 Jul; 18(1):79-85. PubMed ID: 8831999
[TBL] [Abstract][Full Text] [Related]
9. [A phase 2 study of recombinant interleukin 2 (S-6820) for head and neck cancer].
Sawaki S
Gan No Rinsho; 1990 Feb; 36(2):111-20. PubMed ID: 2308207
[TBL] [Abstract][Full Text] [Related]
10. Expansion of activated T-lymphocytes in patients treated with recombinant interleukin 2.
Kolitz JE; Welte K; Wong GY; Holloway K; Merluzzi VJ; Engert A; Bradley EC; Konrad M; Polivka A; Gabrilove JL
J Biol Response Mod; 1987 Aug; 6(4):412-29. PubMed ID: 3498011
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of advanced cancer of the urinary tract with interleukin-2 (IL-2)].
Hara M; Terashima Y; Kanamori S; Senga Y; Kondoh Y; Ohhara M; Tsuboi N; Nishimura T; Akimoto M
Hinyokika Kiyo; 1988 Oct; 34(10):1693-6. PubMed ID: 3266712
[TBL] [Abstract][Full Text] [Related]
12. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
[TBL] [Abstract][Full Text] [Related]
13. [Anti-tumor effects of interleukin 2 against genitourinary cancer--basic study and clinical application].
Marumo K
Hum Cell; 1988 Mar; 1(1):65-70. PubMed ID: 3154016
[TBL] [Abstract][Full Text] [Related]
14. [Soluble interleukin-2 receptor in patients with urinary bladder cancer].
Wen R; Xie S
Zhonghua Zhong Liu Za Zhi; 1996 May; 18(3):224-6. PubMed ID: 9387261
[TBL] [Abstract][Full Text] [Related]
15. [Level and significance of the soluble interleukin-2 receptor expression in serum of patients with bladder cancer].
Wen R; Xie S; Ma P
Zhonghua Wai Ke Za Zhi; 1996 Jan; 34(1):16-8. PubMed ID: 9275680
[TBL] [Abstract][Full Text] [Related]
16. Activation of killer cells from blood of urinary bladder carcinoma patients by short-term treatment with recombinant interleukin 2.
Bubeník J; Kieler J; Tromholt V; Steven K; Indrová M; Toulcová A
Folia Biol (Praha); 1986; 32(3):183-94. PubMed ID: 3488923
[TBL] [Abstract][Full Text] [Related]
17. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
18. Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo.
Redlinger RE; Mailliard RB; Lotze MT; Barksdale EM
J Pediatr Surg; 2003 Mar; 38(3):301-7; discussion 301-7. PubMed ID: 12632339
[TBL] [Abstract][Full Text] [Related]
19. Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period.
Lister J; Rybka WB; Donnenberg AD; deMagalhaes-Silverman M; Pincus SM; Bloom EJ; Elder EM; Ball ED; Whiteside TL
Clin Cancer Res; 1995 Jun; 1(6):607-14. PubMed ID: 9816022
[TBL] [Abstract][Full Text] [Related]
20. Treatment of superficial bladder cancer with intravesical perfusion of rIL-2: a follow-up study.
Ferlazzo G; Magno C; Iemmo R; Rizzo M; Lupo G; Semino C; Bruno S; Melioli G
Anticancer Res; 1996; 16(2):979-80. PubMed ID: 8687163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]